

Receptor occupancy of perospirone is expressed as follows: $\text{Occupancy}(\%) = (\text{BP}_{\text{baseline}} - \text{BP}_{\text{drug}}) / \text{BP}_{\text{baseline}} \times 100$, where $\text{BP}_{\text{baseline}}$ is BP_{ND} in the drug-free state, and BP_{drug} is BP_{ND} after administration of the drug. Mean BP_{ND} of age-matched ten normal male subjects (age range 25–43 years; 34.8 ± 6.7 years, mean \pm SD) measured by the same procedure as for the patients was used as BP_{base} because of the lack of individual baseline BP_{ND} .

The relationship between receptor occupancy and plasma concentration of antipsychotic drug can be expressed as follows: $\text{Occupancy}(\%) = C / (C + \text{EC}_{50}) \times 100$, where C is the plasma concentration of perospirone or ID-15036, and EC_{50} is the concentration required to induce 50% occupancy.

Measurement of plasma concentration of perospirone

Plasma concentrations of perospirone and ID-15036 were determined using a validated high performance liquid chromatography method (Yasui-Furukori et al. 2003; MP-Technopharma Corporation, Fukuoka, Japan). The lower limit of quantification was 0.1 ng/ml for both perospirone and ID-15036.

Healthy subject study

Subjects and study protocol

Four healthy male subjects aged 22–32 years (26.8 ± 4.1 , mean \pm SD) participated in the other part of this study. None had a history of psychiatric, neurological, or somatic disorders. None had taken any medication for at least 2 weeks prior to this study. The baseline PET scan was performed within 2 weeks before taking perospirone. All subjects took a single dose of 16 mg of perospirone, and then three serial PET scans were performed at 1.5, 8, and 25.5 h after its administration. Venous blood samples were taken 11 times, at 0.5, 1.0, 1.5, 2.5, 3.5, 5.0, 6.5, 8.0, 9.0, 25.5, and 26.5 h after perospirone administration, to measure the plasma concentrations of perospirone and ID-15036.

PET procedure

A PET scanner system, ECAT EXACT HR+, was used for all subjects. A head fixation device was used to minimize head movement. Before the dynamic scan, a transmission scan for attenuation correction was performed using a ^{68}Ge - ^{68}Ga source. The dynamic PET scan was performed for 60 min after intravenous bolus injection of 179.6–246.8 MBq (217.0 ± 16.5 MBq, mean \pm SD) of [^{11}C]raclopride. The specific radioactivity of [^{11}C]raclopride was 138.0–320.9 MBq/nmol (235.4 ± 65.8 MBq/nmol, mean \pm SD). T1-weighted images at 1-mm slices of the brain were acquired with 1.5 Tesla MRI, Gyroscan NT.

Data analysis

All emission scan data were reconstructed with a Hanning filter. ROIs were defined for the striatum and cerebellar cortex and were drawn manually on the PET images with reference to individual MR images. The values of ROIs for right and left sides were averaged. BP_{ND} of dopamine D_2 receptor in the striatum was calculated using SRTM. The cerebellum was used as reference tissue. Receptor occupancy was calculated using the individual BP_{ND} values of baseline and drug administration.

Results

Patient study

Dopamine D_2 receptor occupancy of patients with schizophrenia in the temporal cortex ranged from 39.6% to 83.8% (Table 1). Plasma concentrations of perospirone and ID-15036 ranged from 0 to 4.5 and 0.75 to 23.3 ng/ml, respectively. The plasma concentrations of perospirone and ID-15036 were fitted curvilinearly to the dopamine D_2 receptor occupancy (Fig. 1a, b). Estimated EC_{50} values of perospirone and ID-15036 were 0.31 and 1.90 ng/ml, respectively. The total PANSS score ranged from 46 to 81, and the average score of all patients was 66.2 ± 13.4 .




Fig. 1 Relationship between dopamine D_2 receptor occupancy and perospirone (a) and ID-15036 (b) in the patients study

Healthy subject study

Mean dopamine D_2 receptor occupancies in the striatum were $74.8 \pm 8.0\%$ at 1.5 h, $60.1 \pm 5.6\%$ at 8 h, and $31.9 \pm 6.4\%$ at 25.5 h after administration of 16 mg of perospirone in healthy subjects (Fig. 2). The mean plasma concentrations of both perospirone and ID-15036 reached a peak at 1 h after administration, then rapidly decreased, and were not detectable at 25.5 h after (Fig. 3a, b). Estimated half-lives of plasma concentrations of perospirone and ID-15036 were 2.2 and 1.9 h, respectively. No subject complained of severe side effects such as extrapyramidal symptoms or sleepiness.

Discussion

Clinical dose of perospirone

A previous study reported that dopamine D_2 receptor occupancy using [^{11}C]raclopride was 44.4% with 8 mg of perospirone at 1 h post-administration (Sekine et al. 2006). PET studies have suggested that more than 70% dopamine D_2 receptor occupancy is necessary for antipsychotic effect and that 80% occupancy causes extrapyramidal symptoms (Farde et al. 1992; Kapur et al. 2000a; Nordstrom et al. 1993). Two patients (numbers 1 and 5) administered perospirone at 16 mg 2.5 h before PET scanning showed over 70% occupancy. On the other hand, one patient (number 4) taking 8 mg did not reach 70% occupancy in spite of a short interval between the last administration and PET scan. In healthy subjects, a peak of about 75% occupancy was also obtained with 16 mg of perospirone. Although some patients could be maintained at less than 70% occupancy, 16 mg of perospirone seems to be the necessary dose for achieving antipsychotic effect. The plasma concentrations of perospirone and ID-15036 inducing 70% occupancy (EC_{70}) were 0.72 and 4.43 ng/ml, respectively. Side effects could not be evaluated in this study because some patients were taking




Fig. 2 Time course of mean dopamine D_2 receptor occupancy in healthy subject study. Bars represent standard deviation of mean




Fig. 3 Time course of mean plasma concentrations of perospirone (a) and ID-15036 (b) in healthy subjects study. Bars represent standard deviation of mean

benzodiazepines or anti-Parkinson drugs, and plasma prolactin levels were not measured.

Pharmacokinetics and contributions to receptor occupancy of perospirone and ID-15036

In healthy subjects, plasma concentrations of perospirone and ID-15036 peaked at 1 h after administration, with the half-lives of plasma concentrations being 2.2 and 1.9 h, respectively. The plasma concentration of ID-15036 was fourfold that of perospirone. These results were in good agreement with the previous study showing that the T_{max} values were 0.8 (perospirone) and 1.1 h (ID-15036), and $T_{1/2}$ was 1.9 h (perospirone; Yasui-Furukori et al. 2004). As ID-15036 has affinity for the dopamine D_2 receptor ($K_i = 5.84$ nM) and blocks the dopamine D_2 receptor of the in vivo rat brain (Takahashi et al. 1998), both perospirone and ID-15036 contributed to dopamine D_2 receptor occupancy, and the plasma concentrations of both were fitted to the occupancy curve.

Effects of affinity and pharmacokinetics of antipsychotics on time course of receptor occupancy

Dopamine D_2 receptor occupancy was about 75% at 1.5 h after perospirone administration and then showed a rela-

tively rapid decline. After 25.5 h, about 30% occupancy remained, although plasma concentrations of perospirone and ID-15036 were not detectable. The time to reach half of the peak occupancy of 75% was 22 h. The time courses of receptor occupancy and plasma concentration were quite different. In comparison, risperidone and olanzapine showed sustained occupancy; about 80% occupancy 5 or 6 h after administration decreased to only 70% after 24 h (Takano et al. 2004; Tauscher et al. 2002). On the other hand, quetiapine showed transient occupancy; 64% occupancy after 2 h decreased to 0% after 24 h (Kapur et al. 2000b). Some factors such as the time course of plasma concentration of antipsychotics or affinity for dopamine D₂ receptor were considered to affect the time course of receptor occupancy (Kapur and Seeman 2001; Takano et al. 2004). For example, high affinity and long half-life of plasma concentration (e.g., risperidone ($K_i=1.1$ nM, $T_{1/2}=17.8$ h) and olanzapine ($K_i=5.1$ nM, $T_{1/2}=19.5$ h)) expressed sustained occupancy, and low affinity and short half-life of plasma concentration (e.g., quetiapine ($K_i=122$ nM, $T_{1/2}=3.2$ h)) expressed transient occupancy (Gefvert et al. 1998; Seeman 2002; Takano et al. 2004; Tauscher et al. 2002). Perospirone has high affinity for dopamine D₂ receptor and a short half-life of plasma concentration (Takahashi et al. 1998; Yasui-Furukori et al. 2004). These features may cause relatively rapid decrease in occupancy, from 75% at 1.5 h of perospirone administration to 32% after 25.5 h, but the occupancy did not completely disappear within a day. In patients taking 32 mg perospirone (number 6), dopamine D₂ receptor occupancy was 65% at 17.5 h after, supporting an intermediate time course between sustained and transient occupancy.

Possibility of new dosing schedule with perospirone

There are several opinions concerning the dosing schedule of antipsychotics. A recent clinical study reported that extended antipsychotic dosing (every second or third day) was effective and decreased side effects for chronic patients with schizophrenia (Remington et al. 2005). An animal study reported that transient antipsychotic medication was more effective for amphetamine-induced behavioral abnormality than continuous one (Samaha et al. 2008). These findings indicate that sustained occupancy might not necessarily be required for antipsychotic therapy of schizophrenia. In prodromal episode-based intervention, antipsychotic drugs were used occasionally, and long antipsychotic-free periods were sometimes inserted. However, some studies reported that intermittent medication increased the relapse rate in schizophrenia (Gaebel et al. 2002; Herz et al. 1991; Schooler et al. 1997). Because perospirone shows an intermediate time course between sustained and transient occupancy, its single administration may become a new dosing schedule choice

for an antipsychotic drug. Indeed, the administration of perospirone once a day indicated antipsychotic effects and preventions from relapse for chronic patients with schizophrenia (Kusumi et al. 2008). Four patients in the present study (numbers 1, 4, 5, and 6) taking 16 mg or more at least once a day were maintained for more than 6 months. Further study of relationships between clinical response and receptor occupancy of various dosing schedules in patients with schizophrenia will be needed.

Regional difference of dopamine D₂ receptor occupancy

Regional differences of dopamine D₂ receptor occupancy between the striatum and extrastriatum in some second-generation antipsychotic drugs have been discussed (Arakawa et al. 2008; Ito et al. 2009; Pilowsky et al. 1997; Talvik et al. 2001). In the present study, the mean occupancy of four healthy subject and two patients (number 1 and 5) in a short interval between the administration of 16 mg of perospirone and PET scanning seemed to differ very little (75.1% in the striatum with [¹¹C]raclopride and 77.0% in the temporal cortex with [¹¹C]FLB 457). It is suggested that there were no regional differences of dopamine D₂ receptor occupancy between the striatum and extrastriatum with perospirone despite the subjects, study protocols, and radioligands being different.

Conclusion

Sixteen milligrams of perospirone caused over 70% dopamine D₂ receptor occupancy near its peak level, then becoming about half after 22 h. The time courses of receptor occupancy and plasma concentration were quite different. This single dosage may be sufficient for the treatment of schizophrenia and might be useful as a new dosing schedule choice.

Acknowledgments This study was supported by a consignment expense for the Molecular Imaging Program on “Research Base for PET Diagnosis” from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese Government. The sponsors of the study had no role in the study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. All authors took part in the study design, collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the manuscript for publication. All authors saw and approved the final version of the manuscript. All authors reported no biomedical financial interests or potential conflicts of interest. We thank Mr. Katsuyuki Tanimoto, Mr. Takahiro Shiraishi, and Mr. Toshio Miyamoto for their assistance in performing the PET experiments, and Ms. Yoshiko Fukushima for her help as clinical research coordinator at the National Institute of Radiological Sciences. We thank also Mr. Yoshimasa Inoue for measurement of plasma concentration of perospirone at MP-Technopharma Corporation.

References

- Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. *Psychopharmacology (Berl)* 197:229–235
- Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. *Arch Gen Psychiatry* 49:538–544
- Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, Muller P, Muller-Spahn F, Tegeler J (2002) First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. *Schizophr Res* 53:145–159
- Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. *Psychopharmacology (Berl)* 135:119–126
- Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, Mirza M, Vana J (1991) Intermittent vs maintenance medication in schizophrenia. Two-year results. *Arch Gen Psychiatry* 48:333–339
- Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. *J Cereb Blood Flow Metab* 27:1533–1539
- Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. *Int J Neuropsychopharmacol* 12:667–675
- Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d2 receptor explain the action of atypical antipsychotics? A new hypothesis. *Am J Psychiatry* 158:360–369
- Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000a) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry* 157:514–520
- Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000b) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. *Arch Gen Psychiatry* 57:553–559
- Kusumi I, Masui T, Koyama T (2008) Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism. *Prog Neuro-psychopharmacol Biol Psychiatry* 32:520–522
- Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. *Neuroimage* 4:153–158
- Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. *Biol Psychiatry* 33:227–235
- Onrust SV, McClellan K (2001) Perospirone. *CNS Drugs* 15:329–337, discussion 338
- Pilowsky LS, Mulligan RS, Acton PD, Eli PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. *Lancet* 350:490–491
- Remington G, Seeman P, Shammi C, Mann S, Kapur S (2005) “Extended” antipsychotic dosing: rationale and pilot data. *J Clin Psychopharmacol* 25:611–613
- Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. *Biol Psychiatry* 64:145–152
- Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG (1997) Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. *Arch Gen Psychiatry* 54:453–463
- Seeman P (2002) Atypical antipsychotics: mechanism of action. *Can J Psychiatry* 47:27–38
- Sekine Y, Uchi Y, Takei N, Yoshikawa E, Okada H, Minabe Y, Nakamura K, Suzuki K, Iwata Y, Tsuchiya KJ, Sugihara G, Mori N (2006) Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. *J Clin Psychopharmacol* 26:531–533
- Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L (1999) Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. *Int J Neuropsychopharmacol* 2:73–82
- Takahashi Y, Kusumi I, Ishikane T, Koyama T (1998) In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. *J Neural Transm* 105:181–191
- Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. *Int J Neuropsychopharmacol* 7:19–26
- Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [¹¹C]raclopride and [¹¹C]FLB 457. *Am J Psychiatry* 158:926–930
- Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. *Mol Psychiatry* 7:317–321
- Yasui-Furukori N, Inoue Y, Tateishi T (2003) Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* 789:239–245
- Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (2004) Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. *Ther Drug Monit* 26:361–365

Positron Emission Tomography Measurement of Dopamine D₂ Receptor Occupancy in the Pituitary and Cerebral Cortex: Relation to Antipsychotic-Induced Hyperprolactinemia

Ryosuke Arakawa, MD, PhD; Masaki Okumura, MD; Hiroshi Ito, MD, PhD;
Akihiro Takano, MD, PhD; Hidehiko Takahashi, MD, PhD;
Harumasa Takano, MD, PhD; Jun Maeda, PhD;
Yoshiro Okubo, MD, PhD; and Tetsuya Suhara, MD, PhD

Objective: Hyperprolactinemia is a common side effect of antipsychotic drugs used in the treatment of schizophrenia. However, the magnitude of hyperprolactinemia differs among antipsychotics, and there is no reliable mechanism-related marker for the risk of hyperprolactinemia that would allow us to characterize antipsychotics.

Method: In this study, 11 healthy male subjects taking different doses of sulpiride and 24 male patients with DSM-IV–diagnosed schizophrenia taking different antipsychotic drugs (risperidone, olanzapine, haloperidol, and sulpiride) participated. Positron emission tomography scanning using [¹¹C]FLB 457 was performed on all subjects. The dopamine D₂ receptor occupancy of antipsychotics in the pituitary and temporal cortex was calculated. Correlations between plasma concentration of prolactin and dopamine D₂ receptor occupancies were evaluated. The ratio of drug concentration of cerebral receptor site to that of pituitary receptor site (brain/plasma concentration ratio; B/P ratio) was calculated from the receptor occupancies in the 2 regions. Data were collected between November 2001 and September 2007.

Results: Significant positive correlation was observed between the plasma concentration of prolactin and dopamine D₂ receptor occupancy in the pituitary by all 4 antipsychotics ($P = .001$). Dopamine D₂ receptor occupancies of sulpiride were markedly different between the pituitary and temporal cortex, and the B/P ratio for sulpiride (0.34) was significantly lower than for olanzapine ($P = .007$) and risperidone ($P = .015$). Olanzapine had a relatively high B/P ratio (2.70), followed by haloperidol (2.40) and risperidone (1.61).

Conclusions: Dopamine D₂ receptor occupancy in the pituitary is a good indicator of hyperprolactinemia. B/P ratio, indicating the penetrating capability across the blood-brain barrier, seems to be a good characteristic biomarker of each antipsychotic drug for the risk of hyperprolactinemia at therapeutic dose.

J Clin Psychiatry

© Copyright 2010 Physicians Postgraduate Press, Inc.

Submitted: April 17, 2008; accepted April 15, 2009.

Online ahead of print: February 23, 2010 (doi:10.4088/JCP.08m04307yel).

Corresponding author: Tetsuya Suhara, MD, PhD, Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences 4-9-1, Anagawa, Inage-ku, Chiba, 263-8555, Japan (suhara@nirs.go.jp).

Hyperprolactinemia is a commonly encountered side effect of antipsychotic drugs in the treatment of schizophrenia,^{1,2} and several deficits, such as galactorrhea and sexual dysfunction, can result. For women, amenorrhea and infertility are severe adverse effects, and long-term hyperprolactinemia causes osteoporosis in relation to hypogonadism.^{1,3} Hyperprolactinemia is one of the major reasons for discontinuing antipsychotic drugs,⁴ but the risk for this condition varies among them.⁵⁻⁸ It has been reported that antipsychotics such as risperidone and amisulpride showed a high risk, and several factors have been discussed in relation to this risk,⁵⁻⁹ such as affinity for dopamine D₂ receptors^{6,8} and the pharmacodynamics in plasma and brain.⁹

Prolactin secretion is controlled by tonic inhibition of dopamine on tuberoinfundibular neurons.^{10,11} Hyperprolactinemia is reported to be induced by the blocking of dopamine D₂ receptors in the pituitary. As the pituitary is located outside of the blood-brain barrier, drug effects on dopamine D₂ receptors would differ between it and the brain parenchyma.⁹ However, there has been no report about this relation in the living human brain.

Previous positron emission tomography (PET) studies focused on extrapyramidal side effects of antipsychotics induced by over 80% of striatal dopamine D₂ receptor occupancy.¹²⁻¹⁴ Since dopamine D₂ receptor density in the pituitary is low ($B_{\max} = 1.3$ pmol/g tissue) compared to the striatum ($B_{\max} = 16.6$ pmol/g tissue),¹⁵ measurement of dopamine D₂ receptor binding in the pituitary is difficult using a radioligand with relatively low affinity such as [¹¹C]raclopride. [¹¹C]FLB 457 has very high affinity for dopamine D₂ receptors,¹⁶ and since it is used to measure dopamine D₂ receptors in extrastriatal regions where their density is very low,¹⁷⁻²¹ it can also be used to measure dopamine D₂ receptor binding in the pituitary. Although some studies have

reported the visualization or occupancy of human pituitary dopamine D₂ receptors,²²⁻²⁴ the quantification of dopamine D₂ receptor occupancy in the pituitary by several antipsychotics using PET has not been reported.

In this study, we aimed to investigate biomarkers for the potential risk of antipsychotic drug-induced hyperprolactinemia in the living human brain. Dopamine D₂ receptor occupancies in the pituitary and temporal cortex were measured using [¹¹C]FLB 457 by different doses of sulpiride in healthy subjects to examine the dose-occupancy relationship in the 2 regions and by various antipsychotic drugs in patients with schizophrenia to examine the relation with hyperprolactinemia.

METHOD

Subjects and Study Protocol

Study of healthy subjects receiving different doses of sulpiride. Eleven healthy male subjects (age range, 21–40 years; mean ± SD = 27.1 ± 5.8 years) participated in this study. Two PET scans using [¹¹C]FLB 457 were performed before and 3 hours after a single dose of sulpiride at 200 mg (n = 3), 400 mg (n = 3), 600 mg (n = 3), and 800 mg (n = 2). Just before the second PET scan, venous blood samples were taken to measure the plasma concentration of prolactin.

Study of patients with schizophrenia receiving different antipsychotics. Twenty-four male patients (age range, 21–49 years; mean ± SD = 37.1 ± 8.9 years) diagnosed with schizophrenia according to *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)*²⁵ criteria participated in this study. Exclusion criteria were current or past substance abuse, organic brain disease, or epilepsy. Subjects with severe liver or renal dysfunction or who had undergone electroconvulsive therapy within 90 days prior to this study were also excluded. The patients had been taking 1 oral antipsychotic drug at fixed dosage for at least 2 weeks before the start of this study (range, 2 weeks to 11 years; mean, 25 months). Seven patients took risperidone at 2 mg (n = 2), 4 mg (n = 4), and 6 mg (n = 1); 7 patients took olanzapine at 5 mg (n = 2), 10 mg (n = 3), 15 mg (n = 1), and 20 mg (n = 1); 4 patients took haloperidol at 6 mg (n = 2), 9 mg (n = 1), and 12 mg (n = 1); and 6 patients took sulpiride at 200 mg (n = 2), 400 mg (n = 2), 600 mg (n = 1), and 900 mg (n = 1). Antipsychotic treatment was continued during the performance of the PET scans using [¹¹C]FLB 457. The duration between PET scan and the last administration of antipsychotic drug was between 2 hours and 20 hours. Just before PET scan, venous blood samples were taken to measure the plasma concentration of prolactin.

After complete description of this study, written informed consent was obtained from all subjects. The study was approved by the Ethics and Radiation Safety Committee of the National Institute of Radiologic Sciences, Chiba, Japan. Data were collected between November 2001 and September 2007.

Positron Emission Tomography Procedure

A PET scanner system, ECAT EXACT HR+ (CTI-Siemens, Knoxville, Tennessee), was used for all subjects. A head fixation device was used to minimize head movement. A transmission scan for attenuation correction was performed using a ⁶⁸Ge-⁶⁸Ga source before each scan. Dynamic PET scan was performed for 90 minutes after intravenous bolus injection of 155.0–240.1 MBq (mean ± SD = 228.5 ± 72.5 MBq) of [¹¹C]FLB 457. The specific radioactivity of [¹¹C]FLB 457 was 81.6–339.9 GBq/μmol (174.8 ± 63.4 GBq/μmol). Magnetic resonance images (MRIs) of the brain were acquired with 1.5 Tesla MRI, Gyroscan NT (Philips Medical Systems, Best, The Netherlands). T1-weighted images were obtained at 1-mm slices. All subjects were free of organic brain or pituitary lesions.

Data Analysis

All emission scan data were reconstructed with a Hanning filter. Regions of interest (ROIs) were defined for the pituitary, temporal cortex, and cerebellar cortex. The ROIs were drawn manually on PET images with reference to the individual magnetic resonance images. The values of ROIs for the right and left sides were averaged. The temporal cortex was used as the representative brain region because there was little difference in dopamine D₂ receptor occupancy among extrastriatal brain regions.²⁶ Binding potential (BP_{ND}) of dopamine D₂ receptors was calculated from the ratio of the area under the time-activity curve (AUC):

$$BP_{ND} = (AUC_{\text{region}} / AUC_{\text{cerebellum}}) - 1 \text{ (Equation 1)}$$


The subscript “region” denotes the pituitary and temporal cortex. The cerebellum was used as reference tissue given its negligible density of dopamine D₂ receptors.²⁷ In this study, an integration interval of 60 to 90 minutes was used for the calculation of AUC.²⁰

The receptor occupancy of antipsychotic drug is expressed as follows¹⁴:

$$\text{Occupancy (\%)} = (BP_{\text{baseline}} - BP_{\text{drug}}) / BP_{\text{baseline}} \times 100 \text{ (Equation 2)}$$

in which BP_{baseline} is the baseline BP_{ND} in the drug-free state and BP_{drug} is BP_{ND} after the administration of antipsychotic drug. In the healthy subjects study, both BP_{ND} values obtained from each individual were used. In the patients study, the mean BP_{ND} of 15 age-matched healthy male subjects (age range, 21–49 years, mean ± SD = 34.2 ± 8.4 years) was used as BP_{baseline} because of the lack of individual baseline BP_{ND} values. There was no difference in age between healthy subjects and patients (2-tailed *t* test; *P* = .32). There was no age effect of BP_{ND} in the temporal cortex (*P* = .37) and pituitary (*P* = .61) within this age range (21–49 years) of healthy subjects.

Figure 1. Relationship Between Dose of Sulpiride and Dopamine D₂ Receptor Occupancy in the Pituitary or Temporal Cortex in Healthy Subjects^a



^aDopamine D₂ receptors in the pituitary were almost fully occupied even at the lowest dose of sulpiride (200 mg), at which occupancy in the temporal cortex was around 25%. Curves were fitted according to this equation: Occupancy (%) = D / (D + ED₅₀) × 100. ED₅₀ for the pituitary was 22.2 mg and 475.6 mg for the temporal cortex.

The relationship between receptor occupancy and antipsychotic drug dose can be expressed as follows^{18,21}:

$$\text{Occupancy (\%)} = D / (D + ED_{50}) \times 100 \text{ (Equation 3)}$$

in which D is the dose of drug and ED₅₀ is the dose required to induce 50% occupancy.

We calculated the ratio of drug concentration in the cerebral cortex to that in plasma (brain/plasma ratio; B/P ratio), which indicates the penetrating capability of antipsychotic drugs across the blood-brain barrier. Equation 3 can be rewritten as follows:

$$C = IC_{50} / ([100 / \text{Occupancy}] - 1) \text{ (Equation 4)}$$

in which C is the drug concentration in the brain or plasma. IC₅₀ is the drug concentration required to induce 50% occupancy, reflecting the affinity of each antipsychotic drug to dopamine D₂ receptor, and, therefore, IC₅₀ can be assumed to be the same value between the pituitary and the temporal cortex. Because the pituitary exists outside the blood-brain barrier, the B/P ratio can be expressed as follows:

$$\text{B/P ratio} = C_{\text{brain}} / C_{\text{pituitary}} = ([100 / \text{Occupancy}_{\text{pituitary}}] - 1) / ([100 / \text{Occupancy}_{\text{temporal}}] - 1) \text{ (Equation 5)}$$

in which C_{pituitary} is the drug concentration in the vicinity of receptors in the pituitary, and C_{brain} is the drug

concentration in the vicinity of receptors in the temporal cortex. Occupancy_{pituitary} is the dopamine D₂ receptor occupancy in the pituitary, and Occupancy_{temporal} is that in the temporal cortex. The B/P ratio of each antipsychotic drug was calculated.

Prolactin Measurement

The plasma concentration of prolactin was measured by chemiluminescent immunoassay at a commercial laboratory (SRL Inc, Tokyo, Japan). The normal range for males is 3.6–12.8 ng/mL. Values exceeding 12.8 ng/mL were defined as hyperprolactinemia.

Simulation Study

A simulation study was performed in order to estimate the relationship between the B/P ratio and prolactin. First, pituitary occupancy was calculated by Equation 5 according to changes in the B/P ratio when occupancy in the temporal cortex was set at 60%, 70%, and 80%, which was the range of clinical dosage.^{12–14} Next, assumed prolactin values were estimated using linear regression obtained from the patients study. The measured prolactin values in patients (mean temporal cortex occupancy, 66.5 ± 13.9%) were plotted in this simulation graph against the mean B/P ratio of each antipsychotic drug.

Statistics

Correlations between plasma concentration of prolactin and dopamine D₂ receptor occupancy in the pituitary or temporal cortex by the 4 antipsychotic drugs were evaluated using Pearson correlation coefficient. The relationship between occupancy in the pituitary and hyperprolactinemia was evaluated using Fisher exact test. Group differences of B/P ratio among the 4 antipsychotics were evaluated by Kruskal-Wallis test. Multiple comparisons of B/P ratio between the respective antipsychotics were evaluated using the Mann-Whitney U test with Ryan method.


RESULTS

Study of Healthy Subjects Receiving Different Doses of Sulpiride

Dopamine D₂ receptor occupancy in the pituitary by sulpiride ranged from 78.4% to 103.2% (mean ± SD = 96.1 ± 4.6% for 200 mg, 97.1 ± 6.1% for 400 mg, 80.3 ± 1.9% for 600 mg, and 91.1 ± 4.2% for 800 mg), and the occupancy in the temporal cortex ranged from 15.2% to 71.9% (25.4 ± 9.3% for 200 mg, 54.0 ± 21.8% for 400 mg, 55.9 ± 2.9% for 600 mg, and 54.8 ± 17.5% for 800 mg) (Figure 1). ED₅₀ for the pituitary was 22.2 mg and for the temporal cortex was 475.6 mg. The plasma concentration of prolactin ranged from 19.1 to 41.7 ng/mL. The plasma concentration of prolactin for all subjects reached the level of hyperprolactinemia.


Figure 2 shows the mean values of the time-activity curves of the pituitary (predose and postdose of sulpiride),

Figure 2. Time-Activity Curves of the Pituitary (Predose and Postdose), Temporal Cortex (Predose), and Cerebellum in Mean Values of Eleven Healthy Subjects^a



^aIn the pituitary of postdose, the mean value of all dosages was used. The postdose time-activity curve of the pituitary was decreased to a level similar to that of the cerebellum.

Figure 3. Relationship Between Dopamine D₂ Receptor Occupancy in the Pituitary and Plasma Concentration of Prolactin in Patients With Schizophrenia^a




^aSignificant positive correlation was observed between the plasma concentration of prolactin and dopamine D₂ receptor occupancy in the pituitary by different doses of risperidone, olanzapine, haloperidol, and sulpiride ($Y = 0.41X - 4.0$; $P = .001$).

temporal cortex (predose), and cerebellum of the 11 healthy subjects. The curve of the pituitary at postdose was decreased to a level similar to that of the cerebellum.

Study of Patients Receiving Different Antipsychotics

Dopamine D₂ receptor occupancies in the pituitary by risperidone, olanzapine, haloperidol, and sulpiride were 49.2%–80.1%, 18.6%–79.5%, 27.2%–104.4%, and

Figure 4. Relationship Between Dopamine D₂ Receptor Occupancy in the Temporal Cortex and Plasma Concentration of Prolactin in Patients With Schizophrenia^a




^aNo correlation was observed between the plasma concentration of prolactin and dopamine D₂ receptor occupancy in the temporal cortex ($P = .65$).

68.9%–108.4%, respectively, and those in the temporal cortex were 53.4%–79.5%, 50.7%–76.2%, 66.9%–83.2%, and 26.9%–81.8%, respectively. Plasma concentrations of prolactin of patients with risperidone, olanzapine, haloperidol, and sulpiride were 8.9 to 39.9 ng/mL, 3.5 to 23.0 ng/mL, 4.7 to 22.7 ng/mL, and 34.7 to 57.4 ng/mL, respectively. The percentages of hyperprolactinemia of olanzapine, haloperidol, risperidone, and sulpiride were 29% (2/7), 50% (2/4), 86% (6/7), and 100% (6/6), respectively.

Significant positive correlation was observed between the plasma concentration of prolactin and dopamine D₂ receptor occupancy in the pituitary by the 4 antipsychotic drugs ($Y = 0.41X - 4.0$; $r = 0.62$; $P = .001$) (Figure 3). However, no correlation was found between the plasma concentration of prolactin and dopamine D₂ receptor occupancy in the temporal cortex by the 4 antipsychotic drugs ($r = -0.097$; $P = .65$) (Figure 4). When the threshold was set with every 10% of occupancy in the pituitary, patients with hyperprolactinemia could be estimated using Fisher exact test at 50% with the lowest P value ($P = .005$).

The B/P ratio of the 4 antipsychotics differed significantly ($\chi^2_3 = 8.54$; $P = .036$). The mean \pm SD B/P ratios of olanzapine, haloperidol, risperidone, and sulpiride were 2.70 ± 1.84 , 2.40 ± 2.40 , 1.61 ± 1.00 , and 0.34 ± 0.42 , respectively (Figure 5), the same order as the percentages of hyperprolactinemia. The B/P ratios were significantly different in olanzapine versus sulpiride ($U = 2$; $P = .007 < 0.05/6$) and risperidone versus sulpiride ($U = 4$; $P = .015 < 0.05/2$), but haloperidol versus sulpiride did not reach significance ($U = 6$; $P = .20$). Figure 6 shows the PET images of 1 healthy subject and 2 patients, 1 taking olanzapine and

Figure 5. Antipsychotic Drug Concentration Ratio in the Brain to Plasma (B/P ratio) of 4 Drugs in Patients With Schizophrenia^a



^aB/P ratios of olanzapine, haloperidol, risperidone, and sulpiride were mean ± SD = 2.70 ± 1.84, 2.40 ± 2.40, 1.61 ± 1.00, and 0.34 ± 0.42, respectively. B/P ratios were significantly different in olanzapine versus sulpiride ($P = .007$) and risperidone versus sulpiride ($P = .015$), but haloperidol versus sulpiride did not reach significance ($P = .20$).

the other sulpiride. Sulpiride blocked dopamine D₂ receptors to a greater extent in the pituitary than in the temporal cortex, and olanzapine showed relatively less effect in the pituitary.


In the simulation study, drugs with a low B/P ratio induced a high prolactin level at clinical doses with 60%–80% of dopamine D₂ receptor occupancy in the temporal cortex. The measured prolactin values of patients also showed the same tendency (Figure 7). The simulated plasma prolactin level increased when the set value of occupancy in the temporal cortex was increased.

DISCUSSION

In the present study healthy subjects treated with different doses of sulpiride, a marked difference in dopamine D₂ receptor occupancy was confirmed between the pituitary and temporal cortex using the baseline of each. Dopamine D₂ receptors in the pituitary were almost fully occupied even at the lowest dose (200 mg), at which occupancy in the temporal cortex was around 25% (Figure 1). Lipophilicity is a major determinant of the penetrating ability into the brain.²⁸ Since the log P value of sulpiride is reported to be 0.42–1.31, the low brain uptake was considered to be due to lower lipophilicity.^{29,30}

Although nonspecific binding in the pituitary may not be the same as that of the brain parenchyma, the fully occupied time-activity curve of the pituitary was at almost the same level as that of the cerebellum (Figure 2), suggesting that the cerebellum could be used as a measure of nonspecific binding in the pituitary. In the calculation of BP_{ND} in the pituitary, we used the AUC ratio method, which does not

Figure 6. Positron Emission Tomography Images of 1 Healthy Subject and 2 Patients Taking Olanzapine or Sulpiride^a




^aThe 3 positron emission tomography images were axial slices at the pituitary and temporal cortex. High brightness indicates high binding of [¹¹C]FLB 457, meaning less occupied dopamine D₂ receptors. Sulpiride blocked dopamine D₂ receptors in the pituitary more preferentially than in the temporal cortex, whereas olanzapine showed relatively less occupied dopamine D₂ receptors in the pituitary.

require the assumptions that are required for the simplified reference tissue model method (SRTM). The effect of the radiolabeled metabolite of [¹¹C]FLB 457 would be small for the measurement of dopamine D₂ receptors in the pituitary because a previous study indicated that a major metabolite of [¹¹C]FLB 457 had very low affinity for dopamine D₂ receptors.¹⁶ The BP_{ND} values in the temporal cortex were measured by the same method. Binding potential in the extrastriatum by AUC ratio method showed good correlation with those by indirect kinetic method (reported value; $r = 0.96$).²⁰ Although some subjects did not reach equilibrium in the pituitary in this study, the mean value of BP_{ND} in the pituitary was 2.11, almost the same as the reported value in the temporal cortex (2.23) and less than that in the thalamus (3.67), suggesting that the equilibrium would be around the measured time range. Furthermore, the occupancies in the pituitary of patients ($n = 24$) calculated by the SRTM method showed good correlation with those by the AUC ratio method ($r = 0.94$, data not shown). These data suggested that the AUC ratio method can also be used for quantification of the pituitary.

The present study demonstrated that dopamine D₂ receptor occupancy in the pituitary by 4 antipsychotic drugs was significantly correlated with the plasma concentration of prolactin ($Y = 0.41X - 4.0$; $P = .001$) (Figure 3), but no such correlation was found in the temporal cortex (Figure 4). It has been reported that hyperprolactinemia was induced when dopamine D₂ receptor occupancy in the

Figure 7. Simulated Curve Between Antipsychotic Drug Concentration Ratio in the Brain to Plasma (B/P ratio) and Estimated Prolactin Level at Clinical Dosage^a



^aDrug with a low B/P ratio induces a high prolactin level at clinical dosage. Occupancy in the temporal cortex was set at 60%–80%. Prolactin values measured in patients were also plotted against mean B/P ratio, which can be a characteristic index of each antipsychotic drug.

striatum exceeded 50% for raclopride³¹ and 72% for haloperidol.¹² However, no correlation was reported between hyperprolactinemia and striatal or temporal cortex occupancy by amisulpride.³² In this study using Fisher exact test, the patients with hyperprolactinemia could be estimated at 50% with the lowest *P* value (*P* = .005). This indicated that 50% of dopamine D₂ receptor occupancy in the pituitary might represent a threshold level of hyperprolactinemia.

The magnitude of hyperprolactinemia differs among antipsychotics. It has been reported that atypical antipsychotics showed a low risk of hyperprolactinemia as compared to typical antipsychotics.^{1,5,7} Although olanzapine, clozapine, and quetiapine reportedly showed a relatively low risk,^{5–8} risperidone and amisulpride, regarded as atypical antipsychotics, presented a high risk.^{5–8,32} This difference was discussed in relation to the affinity to dopamine D₂ receptors.^{6,8} Risperidone has relatively high affinity, whereas those of olanzapine, clozapine, and quetiapine are medium or low.³³ This order is apparently in accordance with the risk of hyperprolactinemia, although amisulpride has a high risk despite its medium affinity.³³ Thus, after all, the affinity for dopamine D₂ receptors could not conclusively explain the risk of hyperprolactinemia.

A previous animal study suggested that the dissociation between central and peripheral dopamine D₂ receptor occupancy could be a marker of prolactin elevation.⁹ The reported ED₅₀ ratios of the pituitary to the striatum were 654 for amisulpride, 11 for risperidone, and 0.7 for olanzapine, indicating that their respective permeabilities were low, medium, and high. In this study, we calculated the B/P ratio defined as the ratio of antipsychotic drug concentration at the temporal cortex receptor site to that at the pituitary

receptor site to explain the ED₅₀ difference between that in the pituitary and the temporal cortex. It was based on the assumption of fixed IC₅₀, although several factors should be considered concerning the IC₅₀ determination. First, endogenous dopamine may affect the BP_{ND} values of [¹¹C] FLB 457. Some studies reported that dopamine manipulation such as amphetamine challenge did not change BP_{ND},^{34–36} but other studies reported a different conclusion.^{37–42} In this study, we assumed that, compared with amphetamine challenge, antipsychotic drug did not substantially change endogenous dopamine. Second, antipsychotic concentration change during the PET scan may affect the occupancy values according to a previous study.²⁴ Our previous studies reported that there was no regional difference of dopamine D₂ receptor occupancy between the striatum and extrastriatum.⁴³ Moreover, dopamine D₂ receptor densities showed similar values between the temporal cortex and pituitary (B_{max} = 0.4 and 1.3 pmol/g tissue, respectively).¹⁵ In this study, the drug washout rate could be ignored because patient treatment was in the steady-state and receptor densities were close between the 2 sites. Taken together, we assumed that IC₅₀ values were the same between the pituitary and the temporal cortex, and that the antipsychotic drug concentration difference could be estimated.

The order of the B/P ratio in our results was consistent with that of the ED₅₀ ratio in the above-mentioned animal study. The B/P ratio can be the characteristic index of antipsychotic drugs. The concentration of sulpiride in the temporal cortex was one-third of that in the pituitary, while those of olanzapine and haloperidol were about double or triple. Sulpiride had significantly low permeability compared to risperidone (*P* = .015) and olanzapine (*P* = .007), indicating the high risk of hyperprolactinemia for sulpiride.⁵ Although no significant difference of B/P ratio between haloperidol and sulpiride was observed, possible reasons were small sample size and large SD. The order of the B/P ratio was the same as the percentage of hyperprolactinemia in this study. In the simulation study, a drug with low B/P ratio induced a high prolactin level at clinical dosage with 60%–80% of dopamine D₂ receptor occupancy in the temporal cortex (Figure 7). The measured prolactin values of patients showed a similar tendency to the simulated ones. Thus, the B/P ratio seems to be a useful index for predicting the risk of each antipsychotic drug for hyperprolactinemia.

Brain permeability differences are the result of several factors. The Log *P* values of risperidone, olanzapine, and haloperidol are 3.04, 2.89, and 3.36–3.52, respectively,^{30,44,45} and the higher permeability of risperidone, olanzapine, and haloperidol compared to sulpiride (or amisulpride; Log *P* = 1.10–1.70^{29,45}) can be ascribed to high lipophilicity. However, risperidone, in fact, has a slightly higher Log *P* value than olanzapine despite its slightly lower permeability, a seeming contradiction explainable by the fact that risperidone is reportedly a substrate of P-glycoprotein, one of the efflux transporters at the blood-brain barrier.^{46,47}

There were several confounding factors in this study. In the patients study, we used the mean BP_{ND} of healthy control subjects as baseline because previous studies showed no differences in dopamine D₂ receptors in the temporal cortex between patients and healthy subjects^{17,19} or lower binding in patients.^{48,49} A variety of baseline BP_{ND} values can lead to large SD of occupancy or B/P ratio. For example, if BP_{base} changes by $\pm 15\%$,¹⁷ the calculated 50% occupancy could be changed from 41% to 57%. The variety would affect the statistics significantly, especially with the small number of subjects like the haloperidol cases. Furthermore, possible change in the pituitary of patients with schizophrenia⁵⁰ could lead to potential errors in the estimation of occupancy values.

In conclusion, dopamine D₂ receptor occupancies in the pituitary by 4 different antipsychotics were well correlated with the plasma concentration of prolactin. The B/P ratios of the 4 antipsychotics were significantly different. The magnitude of hyperprolactinemia of various antipsychotics can be predicted by the B/P ratio, which indicates the permeability of antipsychotics into the brain. Thus, especially in the area of new drug development, the B/P ratio of each antipsychotic drug might prove to be useful for the early evaluation of the risk of hyperprolactinemia.

Drug names: clozapine (FazaClo, Clozaril, and others), haloperidol (Haldol and others), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal and others).

Author affiliations: Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Drs Arakawa, Okumura, Ito, A. Takano, Takahashi, H. Takano, Maeda, and Suhara); and Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan (Drs Arakawa, Okumura, and Okubo).

Potential conflicts of interest: The authors have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Funding/support: This study was supported by a consignment expense for the Molecular Imaging Program on "Research Base for Positron Emission Tomography (PET) Diagnosis" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese Government.

Role of sponsor: The sponsors of the study had no role in the study design, collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.

Acknowledgment: We thank Mr Katsuyuki Tanimoto, BS, Mr Takahiro Shiraishi, BS, Mr Akira Ando, BS, and Mr Toshio Miyamoto, BS, from the National Institute of Radiological Science in Chiba, Japan, for their assistance in performing the PET experiments, Mr Takashi Okauchi, BS, from the National Institute of Radiological Science in Chiba, Japan, for advice on the statistics, and Ms Yoshiko Fukushima, BS, from the National Institute of Radiological Science in Chiba, Japan, for her help as clinical research coordinator at the National Institute of Radiological Sciences. We also thank Dr Jun Kosaka, MD, from the Sobu Hospital in Chiba, Japan, and Dr Amane Tateno, MD, PhD, Dr Mizuho Sekine, MD, and Dr Hajime Fukuta, MD, from the Nippon Medical School in Tokyo, Japan, for their clinical support. All acknowledged individuals have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

REFERENCES

- Hammer M. The effects of atypical antipsychotics on serum prolactin levels. *Ann Clin Psychiatry*. 2002;14(3):163-173.
- Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. *Curr Med Res Opin*. 2004;20(2):189-197.
- O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? *J Clin Psychopharmacol*. 2005;25(1):26-31.
- Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353(12):1209-1223.
- Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsiveness of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. *Eur Arch Psychiatry Clin Neurosci*. 2001;251(3):141-146.
- Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. *J Clin Psychiatry*. 2005;66(6):761-767.
- Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. *J Clin Psychiatry*. 2004;65(11):1491-1498.
- Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. *J Clin Psychiatry*. 2004;65(1):57-61.
- Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. *J Pharmacol Exp Ther*. 2002;302(3):1129-1134.
- Jaber M, Robinson SW, Missale C, et al. Dopamine receptors and brain function. *Neuropharmacology*. 1996;35(11):1503-1519.
- Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. *Physiol Rev*. 2000;80(4):1523-1631.
- Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D₂ occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry*. 2000;157(4):514-520.
- Nordström AL, Farde L, Wiesel FA, et al. Central D₂-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. *Biol Psychiatry*. 1993;33(4):227-235.
- Farde L, Nordström AL, Wiesel FA, et al. Positron emission tomographic analysis of central D₁ and D₂ dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. *Arch Gen Psychiatry*. 1992;49(7):538-544.
- Kessler RM, Whetsell WO, Ansari MS, et al. Identification of extrastriatal dopamine D₂ receptors in post mortem human brain with [¹²⁵I] epidepride. *Brain Res*. 1993;609(1-2):237-243.
- Halldín C, Farde L, Höglberg T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D₂ dopamine receptors. *J Nucl Med*. 1995;36(7):1275-1281.
- Suhara T, Okubo Y, Yasuno F, et al. Decreased dopamine D₂ receptor binding in the anterior cingulate cortex in schizophrenia. *Arch Gen Psychiatry*. 2002;59(1):25-30.
- Takano A, Suhara T, Yasuno F, et al. The antipsychotic sulpiride is overdosed—a PET study of drug-induced receptor occupancy in comparison with sulpiride. *Int J Neuropsychopharmacol*. 2006;9(5):539-545.
- Talvik M, Nordström AL, Olsson H, et al. Decreased thalamic D₁/D₂ receptor binding in drug-naïve patients with schizophrenia: a PET study with [¹¹C]FLB 457. *Int J Neuropsychopharmacol*. 2003;6(4):361-370.
- Ito H, Sudo Y, Suhara T, et al. Error analysis for quantification of [¹¹C] FLB 457 binding to extrastriatal D₂ dopamine receptors in the human brain. *Neuroimage*. 2001;13(3):531-539.
- Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D₂ receptor occupancy in patients with schizophrenia. *Psychopharmacology (Berl)*. 2008;197(2):229-235.
- Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of ¹⁸F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. *Synapse*. 2002;46(3):170-188.
- Bergström M, Muhr C, Lundberg PO, et al. PET as a tool in the clinical evaluation of pituitary adenomas. *J Nucl Med*. 1991;32(4):610-615.
- Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D₂ receptors by aripiprazole in schizophrenia with PET and [¹⁸F]fallypride. *Neuropsychopharmacology*. 2008;33(13):3111-3125.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition. Washington, DC:

- American Psychiatric Association; 1994.
26. Yasuno F, Suhara T, Okubo Y, et al. Dose relationship of limbic-cortical D₂-dopamine receptor occupancy with risperidone. *Psychopharmacology (Berl)*. 2001;154(1):112–114.
 27. Suhara T, Sudo Y, Okauchi T, et al. Extrastriatal dopamine D₂ receptor density and affinity in the human brain measured by 3D PET. *Int J Neuropsychopharmacol*. 1999;2(2):73–82.
 28. Bickel U. How to measure drug transport across the blood-brain barrier. *NeuroRx*. 2005;2(1):15–26.
 29. Mannhold R, Cruciani G, Dross K, et al. Multivariate analysis of experimental and computational descriptors of molecular lipophilicity. *J Comput Aided Mol Des*. 1998;12(6):573–581.
 30. Hansch C, Sammes P, Taylor J. *Comprehensive Medicinal Chemistry*. Oxford, UK: Pergamon Press; 1990.
 31. Nordström AL, Farde L. Plasma prolactin and central D₂ receptor occupancy in antipsychotic drug-treated patients. *J Clin Psychopharmacol*. 1998;18(4):305–310.
 32. Bressan RA, Erlandsson K, Spencer EP, et al. Prolactinemia is uncoupled from central D₂/D₃ dopamine receptor occupancy in amisulpride treated patients. *Psychopharmacology (Berl)*. 2004;175(3):367–373.
 33. Seeman P. Atypical antipsychotics: mechanism of action. *Can J Psychiatry*. 2002;47(1):27–38.
 34. Okauchi T, Suhara T, Maeda J, et al. Effect of endogenous dopamine on endogenous dopamine on extrastriated [¹¹C]FLB 457 binding measured by PET. *Synapse*. 2001;41(2):87–95.
 35. Tsukada H, Miyasato K, Nishiyama S, et al. Nicotine normalizes increased prefrontal cortical dopamine D₁ receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: a PET study in conscious monkeys. *Neuropsychopharmacology*. 2005;30(12):2144–2153.
 36. Aalto S, Hirvonen J, Kaasinen V, et al. The effects of *d*-amphetamine on extrastriatal dopamine D₂/D₃ receptors: a randomized, double-blind, placebo-controlled PET study with [¹¹C]FLB 457 in healthy subjects. *Eur J Nucl Med Mol Imaging*. 2009;36(3):475–483.
 37. Chou YH, Halldin C, Farde L. Effect of amphetamine on extrastriatal D₂ dopamine receptor binding in the primate brain: a PET study. *Synapse*. 2000;38(2):138–143.
 38. Tsukada H, Nishiyama S, Fukumoto D, et al. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D₁ receptor binding in prefrontal cortex of conscious monkeys. *Neuropsychopharmacology*. 2005;30(10):1861–1869.
 39. Aalto S, Brück A, Laine M, et al. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D₂ receptor ligand [¹¹C]FLB 457. *J Neurosci*. 2005;25(10):2471–2477.
 40. Aalto S, Ihalainen J, Hirvonen J, et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. *Psychopharmacology (Berl)*. 2005;182(3):375–383.
 41. Montgomery AJ, Asselin MC, Farde L, et al. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [¹¹C]FLB 457 PET. *J Cereb Blood Flow Metab*. 2007;27(2):369–377.
 42. Narendran R, Frankle WG, Mason NS, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D₂/D₃ radiotracers [¹¹C]FLB 457 and [¹¹C]fallypride. *Synapse*. 2009;63(6):447–461.
 43. Ito H, Arakawa R, Takahashi H, et al. No regional difference in dopamine D₂ receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. *Int J Neuropsychopharmacol*. 2009;12(5):667–675.
 44. Mannens G, Meuldermans W, Snoeck E, et al. Plasma protein binding of risperidone and its distribution in blood. *Psychopharmacology (Berl)*. 1994;114(4):566–572.
 45. El Ela AA, Härtter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates. *J Pharm Pharmacol*. 2004;56(8):967–975.
 46. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. *Nature*. 2007;446(7137):749–757.
 47. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. *Life Sci*. 2002;71(2):163–169.
 48. Buchsbaum MS, Christian BT, Lehrer DS, et al. D₂/D₃ dopamine receptor binding with [¹⁸F]fallypride in thalamus and cortex of patients with schizophrenia. *Schizophr Res*. 2006;85(1–3):232–244.
 49. Tuppurainen H, Kuikka J, Viinamäki H, et al. Extrastriatal dopamine D₂/D₃ receptor density and distribution in drug-naïve schizophrenic patients. *Mol Psychiatry*. 2003;8(4):453–455.
 50. Dean B, Pavey G, Scarr E, et al. Measurement of dopamine D₂-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia. *Life Sci*. 2004;74(25):3115–3131.

Extrastriatal dopamine D₂ receptor occupancy in olanzapine-treated patients with schizophrenia

Ryosuke Arakawa · Hiroshi Ito · Masaki Okumura ·
Akihiro Takano · Hidehiko Takahashi ·
Harumasa Takano · Yoshiro Okubo · Tetsuya Suhara

Received: 18 September 2008 / Accepted: 9 October 2009 / Published online: 23 October 2009
© Springer-Verlag 2009

Abstract Olanzapine is described as a multi-acting receptor-targeted antipsychotic agent. Although regional differences of dopamine D₂ receptor occupancy, i.e., limbic selectivity, were reported for olanzapine, contradictory results were also reported. We measured dopamine D₂ receptor occupancy of olanzapine in extrastriatal regions in patients with schizophrenia using positron-emission tomography with [¹¹C]FLB457 and the plasma concentrations of olanzapine. Ten patients with schizophrenia taking 5–20 mg/day of olanzapine participated. Dopamine D₂ receptor occupancy in the temporal cortex ranged from 61.1 to 85.8%, and plasma concentration was from 12.7 to 115.4 ng/ml. The ED₅₀ value was 3.4 mg/day for dose and 10.5 ng/ml for plasma concentration. The ED₅₀ values obtained in this study were quite similar to those previously reported in the striatum. In conclusion, although the subjects and methods were different from previous striatal occupancy studies, these results suggest that limbic occupancy by olanzapine may not be so different from that in the striatum.

Keywords Dopamine D₂ receptor occupancy · Extrastriatum · Olanzapine · Positron-emission tomography · Schizophrenia

R. Arakawa · H. Ito · M. Okumura · A. Takano ·
H. Takahashi · H. Takano · T. Suhara (✉)
Molecular Neuroimaging Group, Molecular Imaging Center,
National Institute of Radiological Sciences, 4-9-1, Anagawa,
Inage-ku, Chiba 263-8555, Japan
e-mail: suhara@nirs.go.jp

R. Arakawa · M. Okumura · Y. Okubo
Department of Neuropsychiatry, Nippon Medical School, 1-1-5,
Sendagi, Bunkyo-ku, Tokyo, Japan

Introduction

Olanzapine is a second-generation antipsychotic drug that is widely used in the treatment of schizophrenia [7]. Most second-generation antipsychotic drugs, such as clozapine, risperidone, olanzapine and quetiapine, have high affinity for several kinds of neuroreceptors in addition to dopamine D₂ receptors [6]. Olanzapine has high affinity for dopamine D₂ receptors (K_i = 11 nM) as well as for other receptors, i.e., serotonin 5-HT_{2A} (4 nM), 5-HT_{2C} (11 nM), muscarine m₁–m₅ (1.9–25 nM), adrenaline α₁ (19 nM) and histamine H₁ (7 nM) receptors [6]. The pharmacological profile is similar to that of clozapine, described as a multi-acting receptor-targeted antipsychotic agent. The difference in occupancy of dopamine D₂ receptors with clozapine between striatal and extrastriatal regions has been reported as ‘limbic selectivity’ [23]. This feature was considered one of the reasons for the low risk of extrapyramidal symptoms and a possible effect for negative symptoms [23].

Some animal studies reported greater effects on dopamine D₂ receptors by olanzapine in the extrastriatum than in the striatum [24, 27]. In human studies, higher occupancy in the temporal cortex than in the striatum was also reported for olanzapine [3, 34]. On the other hand, in another human study using olanzapine, no difference in dopamine D₂ receptor occupancies between the striatum and extrastriatum was also reported [16]. In those studies, occupancies in the striatum and extrastriatum were measured from the same data, despite their quite different receptor densities [15].

In the present study, dopamine D₂ receptor occupancy in extrastriatal regions by olanzapine was measured in patients with schizophrenia using positron-emission tomography (PET) with [¹¹C]FLB 457, an optimized

radiotracer for measuring extrastriatal dopamine D₂ receptors [10]. The receptor occupancy in the extrastriatum was compared with that in the striatum by olanzapine previously measured using [¹¹C]raclopride [13].

Methods

Subjects and study protocol

Ten patients, aged 23–47 years (36.2 ± 9.0, mean ± SD), diagnosed with schizophrenia according to DSM-IV criteria, participated in this study (Table 1). After complete explanation of the study, written informed consent was obtained from all patients. Exclusion criteria were current or past substance abuse, organic brain disease or epilepsy. Subjects with severe liver or renal dysfunction, or having undergone electroconvulsive therapy within 90 days prior to this study were also excluded. The patients had been taking fixed dosages of olanzapine for more than 2 weeks before this study. Doses of olanzapine were 5 mg/day in two patients, 7.5 mg/day in two patients, 10 mg/day in three patients, 15 mg/day in one patient and 20 mg/day in two patients. The duration between PET scan and the last administration of olanzapine was between 2 and 20 h. Clinical symptoms were assessed by positive and negative symptom scale (PANSS). This study was approved by the Ethics and Radiation Safety Committee of the National Institute of Radiological Sciences, Chiba, Japan.

PET procedure

A PET scanner system, ECAT EXACT HR+ (CTI-Siemens, Knoxville, TN, USA), was used for all subjects. A head fixation device was used to minimize head

movement. Before the dynamic scan, a transmission scan for attenuation correction was performed using a ⁶⁸Ge–⁶⁸Ga source. The dynamic PET scan was then performed for 90 min after intravenous bolus injection of 197.0–238.0 MBq (217.5 ± 13.9 MBq, mean ± SD) of [¹¹C]FLB 457. The specific radioactivity of [¹¹C]FLB 457 was 85.8–339.9 MBq/nmol (188.0 ± 79.1 MBq/nmol, mean ± SD); the injected mass of FLB 457 was 0.24–0.90 µg (0.64 ± 0.20 µg, mean ± SD). Venous blood samples were taken before and after PET scanning to measure the plasma concentration of olanzapine. The average values of plasma concentration before and after PET scanning were used. The drug concentration of one patient (No. 8) could not be determined because of a technical error. Magnetic resonance images of the brain were acquired with 1.5 T MRI, Gyroscan NT (Philips Medical Systems, Best, Netherlands). T1-weighted images of 1-mm slices were obtained.

Data analysis

All emission scan data were reconstructed with a Hanning filter. Regions of interest (ROIs) were defined for the temporal cortex as for the extrastriatal region and cerebellar cortex [3, 34]. ROIs were drawn manually on PET images with reference to individual MR images. The values of ROIs for right and left sides were averaged. Binding potential (BP_{ND}) of dopamine D₂ receptor was calculated using a three-parameter simplified reference tissue model [18]. The cerebellum was used as reference tissue because of its negligible density of dopamine D₂ receptors [28].

Receptor occupancy of antipsychotic drug is expressed as follows: Occupancy (%) = (BP_{base} - BP_{drug})/BP_{base} × 100, where BP_{base} is BP_{ND} in the drug-free state and BP_{drug} is BP_{ND} after administration of the drug. In this study,

Table 1 Patient characteristics, plasma concentration of olanzapine, and dopamine D₂ receptor occupancy

No.	Age (years)	Sex	Duration of illness (years)	PANSS	Dose (mg/day)	Duration of fixed dose (months)	Other medication	Plasma concentration (ng/ml)	Receptor occupancy (%)
1	41	M	6.5	50	5	14	–	20.1	61.6
2	45	M	8	38	5	25	BZ	12.7	72.2
3	30	F	12	49	7.5	13	–	25.9	65.6
4	45	F	4	95	7.5	0.5	BZ, AP	25.5	76.9
5	23	M	0.8	50	10	7	–	48.5	69.7
6	41	M	17	44	10	30	BZ	21.8	61.1
7	47	M	27	92	10	3	–	44.5	81.8
8	32	M	17	75	15	16	BZ	ND	67.9
9	23	M	5	101	20	0.5	BZ	61.0	79.5
10	37	F	11	92	20	3	BZ	115.4	85.8

BZ benzodiazepine, AP anti-parkinsonian drug, ND not determined

mean BP_{ND} of age-matched ten normal male subjects (age range 21–49; 36.2 ± 9.1 years, mean \pm SD) measured by the same procedure as for the patients was used as BP_{base} because of the lack of individual baseline BP_{ND} .

The relationship between receptor occupancy and dose (or plasma concentration) of antipsychotic drug can be expressed as follows:

$$\text{Occupancy}(\%) = D / (D + ED_{50}) \times 100,$$

where D is the dose of olanzapine and ED_{50} is the dose required to induce 50% occupancy [1, 13, 31]. In this study, maximum occupancy was fixed at 100%, the same as previous occupancy studies with olanzapine [13].

Measurement of plasma concentration of olanzapine

Plasma concentrations of olanzapine were determined using a validated high-performance liquid chromatography (HPLC) method (JCL Bioassay Corporation., Hyogo, Japan).

Statistical analysis

Correlations between dopamine D_2 receptor occupancy in the temporal cortex and daily dose, plasma concentration, age, duration of illness and PANSS (total or sub scores) were assessed using Pearson's correlation coefficient.

Results

Dopamine D_2 receptor occupancy in the temporal cortex ranged from 61.1 to 85.8% (Table 1). Plasma concentration of olanzapine ranged from 12.7 to 115.4 ng/ml. ED_{50} was 3.4 mg/day for the daily dose (Fig. 1) and 10.5 ng/ml for




Fig. 1 Relationship between dopamine D_2 receptor occupancy and daily dose of olanzapine




Fig. 2 Relationship between dopamine D_2 receptor occupancy and plasma concentration of olanzapine

the plasma concentration (Fig. 2). The PANSS score ranged from 38 to 101. Average PANSS scores of all patients were 68.6 ± 24.7 .

A positive correlation was observed between dopamine D_2 receptor occupancy in the temporal cortex and plasma concentration ($r = 0.72$, $P = 0.029$), but not daily dose within this dose range ($r = 0.57$, $P = 0.082$). A positive correlation was also observed with total PANSS scores ($r = 0.80$, $P = 0.0054$), positive scores ($r = 0.78$, $P = 0.0074$), negative scores ($r = 0.68$, $P = 0.032$), and general scores ($r = 0.78$, $P = 0.0072$). No correlations were observed between dopamine D_2 receptor occupancy in the temporal cortex and age ($P = 0.85$) or duration of illness ($P = 0.81$).

Discussion

Although the measured occupancy value was above 50% with 5–20 mg/day of olanzapine, the calculated ED_{50} value from the present result in the temporal cortex was 3.4 mg/day for the daily dose and 10.5 ng/ml for the plasma concentration. The previously reported ED_{50} of olanzapine in the striatum was 4.5 mg/day for the daily dose and 10.3 ng/ml for the plasma concentration [13]. ED_{50} of plasma concentration in the extrastriatum of the present study was similar to that reported in the striatum, meaning that there was no noteworthy regional difference in dopamine D_2 receptor occupancy by olanzapine between the striatum and extrastriatum. Based on 70–80% of dopamine D_2 receptor occupancy [8, 14, 20], the optimal daily dose of olanzapine would be about 8–14 mg/day. This estimated dose was in fairly good agreement with the current clinical dose (5–20 mg/day in Japan).

According to electrophysiological measurement, the effect of olanzapine was reported preferentially in the ventral tegmental area (A10) [27], and olanzapine was reported to increase c-fos expression to a greater degree in the nucleus accumbens than in the dorsolateral striatum [24]. These findings suggested that olanzapine had preferentially different regional effects for extrastriatal regions. The concept of ‘limbic selectivity’, i.e., differences in dopamine D₂ receptor occupancy between the striatum and extrastriatum, has been discussed. Although there are several reports about ‘limbic selectivity’ of second-generation antipsychotics, such as clozapine [9, 17, 23, 34], risperidone [5, 34], quetiapine [17, 26] and amisulpride [4, 34], it has also been reported that there is no limbic selectivity with second-generation antipsychotics such as clozapine [32] and risperidone (and paliperidone) [1, 11, 35].

Contradictory results of limbic selectivity have also been reported for olanzapine. Two studies showed higher occupancy in the temporal cortex than in the striatum using [¹²³I]epidepride SPECT (82.8 ± 4.2% in the temporal cortex and 41.3 ± 17.9% in the striatum) [3] and [⁷⁶Br]FLB 457 PET (83.6 ± 10.5% in the temporal cortex and 45.1 ± 20.9% in the striatum) [34]. On the other hand, no significant difference in occupancy between the temporal cortex (67.5 ± 7.1%) and striatum (70.9 ± 6.9%) was reported using [¹⁸F]fallypride PET [16]. Regional differences in occupancies were calculated from the area under the time-activity curve ratio in [¹²³I]epidepride SPECT and [⁷⁶Br]FLB 457 PET [3, 34]. A previous study reported that the ratio method underestimated striatal occupancy using high-affinity radioligand such as [¹²³I]epidepride or [¹¹C]FLB 457 (probably also [⁷⁶Br]FLB 457) because radioligand bindings did not reach equilibrium due to the high density of dopamine D₂ receptors in the striatum [21]. In addition, because none of the studies concerning regional difference of occupancy by olanzapine presented plasma concentrations [3, 16, 34], ED₅₀ of the extrastriatum could not be compared with the present study.

Differences of occupancy or EC₅₀ values in the same brain region (e.g. striatum) were reported using different radioligands (“Discussion” in [19]). As commented above, this difference may be caused using different affinity radioligands at high-density receptor regions [21]. In this study, the dopamine D₂ receptor bindings in the temporal cortex were measured using [¹¹C]FLB 457 because the dopamine D₂ receptor density of the temporal cortex is very low compared with that of the striatum ($B_{\max} = 0.4$ and 16.6 pmol/g tissue, respectively) [15]. Recently, the absence of regional difference between striatal and extrastriatal occupancy of risperidone was reported using

[¹¹C]raclopride and [¹¹C]FLB 457 by precise methods [11]. These results suggest that optimal radioligands are necessary for different brain regions with different receptor densities.

The significant positive correlation between temporal dopamine D₂ receptor occupancy and PANSS suggests that higher doses tend to be used for severe symptoms of schizophrenia. However, as this was an open study and the number of patients was limited, further studies (such as randomized controlled trials) are needed.

In the present study, the mean BP_{ND} value of age-matched healthy subjects was used as value of the drug-free state. Although previous studies showed no difference in BP_{ND} values of the temporal cortex between normal subjects and patients with schizophrenia [29, 33] or between the sexes [12], individual differences in BP_{ND} values may lead to potential error in the estimation of dopamine D₂ receptor occupancy [8]. Moreover, there is a possibility of upregulation of dopamine D₂ receptor by neuroleptic treatment [25]. When BP_{base} changes by ±15%, the estimated occupancy ranges from 41 to 57% for an assumed occupancy of 50%. The effect of displaceable binding of [¹¹C]FLB 457 in the cerebellum may also lead to an underestimation of receptor occupancy [2, 22].

Although the time point of the scan following the last drug administration was different among the scans, plasma concentration was measured and the reported time-course of occupancy of olanzapine fitted well with the occupancy simulated by plasma concentration [30].

In conclusion, dopamine D₂ receptor occupancy ranged from 61.1 to 85.8% in the temporal cortex of patients with schizophrenia taking 5–20 mg/day of olanzapine. The ED₅₀ values were 3.4 mg/day for dose and 10.5 ng/ml for plasma concentration of olanzapine, in fairly good agreement with the reported values in the striatum using [¹¹C]raclopride. Although the subjects and methods were different from previous striatal occupancy studies, these results suggest that limbic occupancy by olanzapine may not be so different from that in the striatum.

Acknowledgments This study was supported by a consignment expense for the Molecular Imaging Program on “Research Base for PET Diagnosis” from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese Government. We thank Mr. Katsuyuki Tanimoto, Mr. Takahiro Shiraishi, Mr. Akira Ando, and Mr. Toshio Miyamoto for their assistance in performing the PET experiments, and Ms. Yoshiko Fukushima for her help as clinical research coordinator at the National Institute of Radiological Sciences. We thank also Dr. Amane Tateno, Dr. Mizuho Sekine, and Dr. Hajime Fukuta for their clinical support.

Conflict of interest statement All authors reported no conflict of interest.

References

1. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. *Psychopharmacology (Berl)* 197:229–235
2. Asselin MC, Montgomery AJ, Grasby PM, Hume SP (2007) Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [¹¹C]FLB 457: re-evaluation of the validity of using a cerebellar reference region. *J Cereb Blood Flow Metab* 27:378–392
3. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Eil PJ, Gacinovic S, Kerwin RW, Pilowsky LS (2000) Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [¹²³I]epidepride single photon emission tomography (SPET) study. *Psychopharmacology (Berl)* 150:132–140
4. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Eil PJ, Pilowsky LS (2003) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [¹²³I]epidepride SPET study of amisulpride-treated patients. *Am J Psychiatry* 160:1413–1420
5. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Eil PJ, Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [¹²³I]-epidepride SPET study. *J Clin Psychopharmacol* 23:5–14
6. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. *Neuropsychopharmacology* 14:87–96
7. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S (2005) Olanzapine for schizophrenia. *Cochrane Database Syst Rev* CD001359
8. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. *Arch Gen Psychiatry* 49:538–544
9. Grunder G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Hartter S, Schreckenberger M, Stoeter P, Hiemke C, Rosch F, Wong DF, Bartenstein P (2006) The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. *Neuropsychopharmacology* 31:1027–1035
10. Ito H, Sudo Y, Suhara T, Okubo Y, Halldin C, Farde L (2001) Error analysis for quantification of [¹¹C]FLB 457 binding to extrastriatal D2 dopamine receptors in the human brain. *Neuroimage* 13:531–539
11. Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. *Int J Neuropsychopharmacol* 12:667–675
12. Kaasinen V, Nagren K, Hietala J, Farde L, Rinne JO (2001) Sex differences in extrastriatal dopamine d2-like receptors in the human brain. *Am J Psychiatry* 158:308–311
13. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT₂ and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. *Am J Psychiatry* 155:921–928
14. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry* 157:514–520
15. Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clanton JA, Schmidt DE, Mason NS, Manning RG (1993) Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [¹²⁵I]epidepride. *Brain Res* 609:237–243
16. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. *Neuropsychopharmacology* 30:2283–2289
17. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. *Neuropsychopharmacology* 31:1991–2001
18. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. *Neuroimage* 4:153–158
19. Meisenzahl EM, Schmitt G, Grunder G, Dresel S, Frodl T, la Fougere C, Scheuerecker J, Schwarz M, Boerner R, Stauss J, Hahn K, Moller HJ (2008) Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. *Pharmacopsychiatry* 41:169–175
20. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. *Biol Psychiatry* 33:227–235
21. Olsson H, Farde L (2001) Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy—a simulation study based on experimental data. *Neuroimage* 14:936–945
22. Olsson H, Halldin C, Farde L (2004) Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. *Neuroimage* 22:794–803
23. Pilowsky LS, Mulligan RS, Acton PD, Eil PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. *Lancet* 350:490–491
24. Robertson GS, Fibiger HC (1996) Effects of olanzapine on regional C-Fos expression in rat forebrain. *Neuropsychopharmacology* 14:105–110
25. Schroder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, Geider FJ, Sauer H (1998) D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. *Biol Psychiatry* 43:660–665
26. Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Eil PJ, Kerwin RW, Pilowsky LS (2000) Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo. [¹²³I]-epidepride single photon emission tomography (SPET) study. *Br J Psychiatry* 177:408–415
27. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. *Neuropsychopharmacology* 14:97–105
28. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L (1999) Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. *Int J Neuropsychopharmacol* 2:73–82
29. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. *Arch Gen Psychiatry* 59:25–30
30. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. *Int J Neuropsychopharmacol* 7:19–26

- 31. Takano A, Suhara T, Yasuno F, Suzuki K, Takahashi H, Morimoto T, Lee YJ, Kusahara H, Sugiyama Y, Okubo Y (2006) The antipsychotic sultopride is overdosed—a PET study of drug-induced receptor occupancy in comparison with sulpiride. *Int J Neuropsychopharmacol* 9:539–545
- 32. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [¹¹C]raclopride and [¹¹C]FLB 457. *Am J Psychiatry* 158:926–930
- 33. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003) Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [¹¹C]FLB 457. *Int J Neuropsychopharmacol* 6:361–370
- 34. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML (2001) Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *Br J Psychiatry* 179:503–508
- 35. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, Tanada S (2001) Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. *Psychopharmacology (Berl)* 154:112–114

Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[¹⁸F]FMeNER-D₂

Mizuho Sekine · Ryosuke Arakawa · Hiroshi Ito · Masaki Okumura · Takeshi Sasaki · Hidehiko Takahashi · Harumasa Takano · Yoshiro Okubo · Christer Halldin · Tetsuya Suhara

Received: 20 August 2009 / Accepted: 3 March 2010 / Published online: 23 March 2010
© Springer-Verlag 2010

Abstract

Rationale Central norepinephrine transporter (NET) is one of the main targets of antidepressants. Although the measurement of NET occupancy has been attempted in humans, the outcomes have been inconclusive.

Objective In this study, the occupancy of NET by different doses of an antidepressant, nortriptyline, was measured using positron emission tomography (PET) with (S,S)-[¹⁸F]FMeNER-D₂.

Materials and methods PET scans using (S,S)-[¹⁸F]FMeNER-D₂ were performed on six healthy men before and after oral administration of a single oral dose of nortriptyline (10–75 mg). After a bolus i.v. injection of (S,S)-[¹⁸F]FMeNER-D₂, dynamic scanning was performed for 0–90 min, followed by scanning for 120–180 min. The ratio of the thalamus-to-caudate areas under the curve (120–180 min) minus 1 was used as the binding potential (BP_{ND}) for NET. NET occupancy was calculated as the percentage

reduction of BP_{ND}. Venous blood samples were taken to measure the concentrations of nortriptyline just before injection of the tracer and at 180 min after the injection.

Results Mean NET occupancies by nortriptyline were 16.4% at 10 mg, 33.2% at 25 mg, and 41.1% at 75 mg. The mean plasma concentration of nortriptyline was less than the lower limit of detection at 10 mg, 23.7 ng/mL at 25 mg, and 50.5 ng/mL at 75 mg. Estimated ED₅₀ was 76.8 mg of administration dose and 59.8 ng/mL of plasma concentration.

Conclusions NET occupancy by nortriptyline corresponding to the administration dose of 10–75 mg or plasma concentration was observed from 16% to 41%.

Keywords Norepinephrine transporter · (S,S)-[¹⁸F]FMeNER-D₂ · Positron emission tomography · Occupancy · Nortriptyline

M. Sekine · R. Arakawa · H. Ito (✉) · M. Okumura · T. Sasaki · H. Takahashi · H. Takano · T. Suhara
Molecular Neuroimaging Group, Molecular Imaging Center,
National Institute of Radiological Sciences,
4-9-1, Anagawa, Inage-ku,
Chiba 263-8555, Japan
e-mail: hito@nirs.go.jp

M. Sekine
e-mail: sekine@nirs.go.jp

M. Sekine · R. Arakawa · M. Okumura · Y. Okubo
Department of Neuropsychiatry, Nippon Medical School,
Tokyo, Japan

C. Halldin
Department of Clinical Neuroscience, Psychiatry Section,
Karolinska Institutet, Karolinska Hospital,
Stockholm, Sweden

Introduction

Norepinephrine, one of the monoamine neurotransmitters in the central nervous system, has been reported to be related to several functions such as memory, cognition, consciousness, and emotion (Harmer et al. 2004; Southwick et al. 2002; Strange et al. 2003). It plays important roles in the pathophysiology of depression (Nutt 2006). Norepinephrine transporter (NET) is responsible for the reuptake of norepinephrine into presynaptic nerves and is one of the main targets of antidepressants. Serotonin transporter (5-HTT) is another main target of antidepressants. Positron emission tomography (PET) studies, using radioligands such as [¹¹C]McN(+)-5652 and [¹¹C]DASB, have made it possible to measure the occupancy of 5-HTT by antide-

pressants in living human brain (Meyer et al. 2001, 2004; Suhara et al. 2003). 5-HTT occupancy was reported to be over 80% at clinical doses of selective serotonin reuptake inhibitors (SSRIs) during the treatment of depression (Meyer et al. 2001, 2004; Suhara et al. 2003; Takano et al. 2006). On the other hand, although the measurement of NET occupancy has been attempted in humans, the outcomes have been inconclusive (Logan et al. 2007). (S,S)-[¹⁸F]FMeNER-D₂ was recently developed as a radioligand for the measurement of NET binding with PET (Schou et al. 2004), allowing estimation of NET bindings quantitatively in the human brain (Arakawa et al. 2008; Takano et al. 2008a, b).

Nortriptyline is one of the tricyclic antidepressants and is widely used for treatment of depression. The binding affinity of nortriptyline for NET is higher ($K_i=1.49$ nmol/L) than other monoamine transporters, e.g., 5-HTT ($K_i=18.0$ nmol/L) and dopamine transporter ($K_i=1,200$ nmol/L) (Vaishnavi et al. 2004). Thus, nortriptyline can be considered a relatively NET-selective antidepressant. In this study, we investigated the degree of NET occupancy by different doses of the antidepressant, nortriptyline, using PET with (S,S)-[¹⁸F]FMeNER-D₂.

Materials and methods

Subjects

Six healthy male subjects (age range, 22–39 years; mean \pm SD, 30.5 ± 6.3 years) participated in this study. All subjects were free of any somatic, neurological, or psychiatric disorders, and they had no history of current or previous drug abuse. After complete description of this study, written informed consent was obtained from all subjects. The study was approved by the Ethics and Radiation Safety Committees of the National Institute of Radiological Sciences, Chiba, Japan.

PET procedures

The first PET scan with (S,S)-[¹⁸F]FMeNER-D₂ was performed before nortriptyline administration. The second PET scan was performed 5 h after single-dose oral administration. These two scans were carried out at the same time on separate days. The average interval between these two scans was 6.5 days (range, 2–14 days). The nortriptyline doses were 10, 25, and 75 mg in two subjects each. An ECAT EXACT HR+ (CTI-Siemens, Knoxville, TN, USA) PET scanner system was used for all measurements. A head fixation device was used to minimize head movement. A transmission scan for attenuation correction was performed using a ⁶⁸Ge-⁶⁸Ga source. Dynamic PET

scans were performed after a bolus injection of 183.0–196.5 MBq (mean \pm SD, 188.9 ± 4.2 MBq) of (S,S)-[¹⁸F]FMeNER-D₂. Specific radioactivity of (S,S)-[¹⁸F]FMeNER-D₂ was 65.4–344.1 GBq/ μ mol (192.6 ± 86.4 GBq/ μ mol). Brain radioactivities were measured from 0 to 90 min (1 min \times 10, 2 min \times 15, and 5 min \times 10), followed by scanning for 120–180 min (10 min \times 6).

Magnetic resonance (MR) images of the brain were acquired with a 1.5 Tesla MR scanner, Gyroscan NT (Philips Medical Systems, Best, Netherlands). T1-weighted images were obtained at 1-mm slices.

Measurement of plasma concentration of nortriptyline

Venous blood samples were taken to measure the plasma concentrations of nortriptyline just before injection of the radioligand and at 180 min after the injection. The average values of these two samples were used in this study. The plasma concentrations of nortriptyline were determined by gas chromatography–mass spectrometry with a lower limit of quantification of 20.0 ng/mL (Mitsubishi Chemical Medience Corporation, Tokyo, Japan).

Data analysis

All emission scans were reconstructed with a Hanning filter (cutoff frequency: 0.4 cycle/pixel). All MR images were co-registered to the PET images using a statistical parametric mapping (SPM2) system. Regions of interest were drawn manually on the thalamus, hippocampus, anterior cingulate cortex (ACC), locus coeruleus (LC), and the caudate in each of the summed PET images with reference to the co-registered MR image. Regional radioactivity was calculated for each frame, corrected for decay, and plotted versus time.

(S,S)-[¹⁸F]FMeNER-D₂ bindings were expressed as binding potentials relative to non-displaceable binding (BP_{ND}) (Innis et al. 2007). BP_{ND} of (S,S)-[¹⁸F]FMeNER-D₂ in the thalamus, hippocampus, ACC, and LC were calculated using the simplified reference tissue model method (SRTM; Lammertsma and Hume 1996), multilinear reference tissue model method (MRTM; Ichise et al. 2003), and the area under the curve (AUC) ratio method. We used the caudate as reference brain region in all methods because of its negligible NET density (Donnan et al. 1991; Logan et al. 2007; Schou et al. 2005). In the AUC ratio method, BP_{ND} can be expressed as:

$$BP_{ND} = \frac{AUC_{(regions)}}{AUC_{(caudate)}} - 1,$$

where $AUC_{(regions)}$ is the area under the time-activity curve of the target regions, and $AUC_{(caudate)}$ is that of the caudate. An integration interval of 120–180 min was used in this